company background image

Ainos OTCPK:AIMD Stock Report

Last Price


Market Cap







07 Aug, 2022


Company Financials
AIMD fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health3/6

AIMD Stock Overview

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications.

Ainos Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ainos
Historical stock prices
Current Share PriceUS$0.70
52 Week HighUS$1.20
52 Week LowUS$0.083
1 Month Change75.00%
3 Month Change42.86%
1 Year Change-26.32%
3 Year Change57.23%
5 Year Change150.00%
Change since IPO-99.26%

Recent News & Updates

Shareholder Returns

AIMDUS BiotechsUS Market

Return vs Industry: AIMD underperformed the US Biotechs industry which returned -24.5% over the past year.

Return vs Market: AIMD underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is AIMD's price volatile compared to industry and market?
AIMD volatility
AIMD Average Weekly Movement103.3%
Biotechs Industry Average Movement12.9%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: AIMD is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 46% a day.

Volatility Over Time: AIMD's weekly volatility has increased from 68% to 103% over the past year.

About the Company

198435Chun-Hsien Tsai

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.

Ainos Fundamentals Summary

How do Ainos's earnings and revenue compare to its market cap?
AIMD fundamental statistics
Market CapUS$101.07m
Earnings (TTM)-US$5.45m
Revenue (TTM)US$679.64k


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AIMD income statement (TTM)
Cost of RevenueUS$224.01k
Gross ProfitUS$455.63k
Other ExpensesUS$5.91m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.038
Gross Margin67.04%
Net Profit Margin-802.56%
Debt/Equity Ratio387.1%

How did AIMD perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is AIMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AIMD?

Other financial metrics that can be useful for relative valuation.

AIMD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue192x
Enterprise Value/EBITDA-58.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does AIMD's PB Ratio compare to its peers?

AIMD PB Ratio vs Peers
The above table shows the PB ratio for AIMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.3x
OCX OncoCyte
SLDB Solid Biosciences
ATNM Actinium Pharmaceuticals
MBIO Mustang Bio
AIMD Ainos

Price-To-Book vs Peers: AIMD is expensive based on its Price-To-Book Ratio (12.5x) compared to the peer average (1.3x).

Price to Earnings Ratio vs Industry

How does AIMD's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: AIMD is expensive based on its Price-To-Book Ratio (12.5x) compared to the US Biotechs industry average (1.8x)

Price to Book Ratio vs Fair Ratio

What is AIMD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AIMD PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio12.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AIMD's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of AIMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AIMD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AIMD's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Ainos forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ainos has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Take a look at our analysis of AIMD’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Ainos's filings and announcements here.

Past Performance

How has Ainos performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AIMD is currently unprofitable.

Growing Profit Margin: AIMD is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: AIMD is unprofitable, and losses have increased over the past 5 years at a rate of 36% per year.

Accelerating Growth: Unable to compare AIMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AIMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).

Return on Equity

High ROE: AIMD has a negative Return on Equity (-67.49%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Ainos's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AIMD's short term assets ($3.0M) do not cover its short term liabilities ($5.7M).

Long Term Liabilities: AIMD's short term assets ($3.0M) do not cover its long term liabilities ($26.9M).

Debt to Equity History and Analysis

Debt Level: AIMD's net debt to equity ratio (364%) is considered high.

Reducing Debt: AIMD had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AIMD has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: AIMD is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies


What is Ainos's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AIMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AIMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AIMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AIMD's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AIMD has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Chun-Hsien Tsai (52 yo)





Mr. Chun-Hsien Tsai has been Chairman of Board, President and Chief Executive Officer at Ainos, Inc. since April 15, 2021 and served as its Chief Financial Officer since April 15, 2021 until August 11, 202...

CEO Compensation Analysis

Compensation vs Market: Chun-Hsien's total compensation ($USD81.62K) is below average for companies of similar size in the US market ($USD767.73K).

Compensation vs Earnings: Insufficient data to compare Chun-Hsien's compensation with company performance.

Leadership Team

Experienced Management: AIMD's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Experienced Board: AIMD's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Ainos, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Ainos, Inc.
  • Ticker: AIMD
  • Exchange: OTCPK
  • Founded: 1984
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$101.066m
  • Shares outstanding: 144.38m
  • Website:

Number of Employees


  • Ainos, Inc.
  • 8880 Rio San Diego Drive
  • Suite 800
  • San Diego
  • California
  • 92108
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.